Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of “Moderate Buy” by Analysts

Relay Therapeutics, Inc. (NASDAQ:RLAY) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $17.00.

A number of equities analysts have recently commented on the company. Wells Fargo & Company upgraded Relay Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $6.00 to $13.00 in a report on Friday, December 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th.

Relay Therapeutics Stock Down 2.2%

NASDAQ:RLAY opened at $7.43 on Wednesday. The company has a market cap of $1.29 billion, a P/E ratio of -4.25 and a beta of 1.55. The firm’s 50 day moving average is $7.84 and its two-hundred day moving average is $5.86. Relay Therapeutics has a fifty-two week low of $1.77 and a fifty-two week high of $9.04.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Research analysts forecast that Relay Therapeutics will post -2.55 earnings per share for the current fiscal year.

Insider Buying and Selling at Relay Therapeutics

In related news, insider Donald A. Bergstrom sold 30,897 shares of the stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $7.29, for a total value of $225,239.13. Following the completion of the sale, the insider directly owned 521,823 shares in the company, valued at approximately $3,804,089.67. This represents a 5.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sanjiv Patel sold 43,168 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $7.82, for a total value of $337,573.76. Following the completion of the transaction, the chief executive officer directly owned 661,041 shares in the company, valued at $5,169,340.62. This trade represents a 6.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 198,331 shares of company stock worth $1,455,204 over the last three months. 4.32% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Relay Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Cresset Asset Management LLC grew its stake in Relay Therapeutics by 5.0% in the third quarter. Cresset Asset Management LLC now owns 38,932 shares of the company’s stock worth $203,000 after purchasing an additional 1,848 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in Relay Therapeutics by 8.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 27,871 shares of the company’s stock worth $145,000 after buying an additional 2,079 shares during the last quarter. Prelude Capital Management LLC grew its position in shares of Relay Therapeutics by 18.7% in the 3rd quarter. Prelude Capital Management LLC now owns 19,700 shares of the company’s stock worth $103,000 after acquiring an additional 3,100 shares in the last quarter. Los Angeles Capital Management LLC grew its position in shares of Relay Therapeutics by 5.0% in the 2nd quarter. Los Angeles Capital Management LLC now owns 68,615 shares of the company’s stock worth $237,000 after acquiring an additional 3,275 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Relay Therapeutics by 17.8% in the 3rd quarter. SG Americas Securities LLC now owns 31,945 shares of the company’s stock valued at $167,000 after acquiring an additional 4,825 shares during the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.